Concentrix (NASDAQ:CNXC) Releases FY 2025 Earnings Guidance

Concentrix (NASDAQ:CNXC - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 11.530-11.760 for the period, compared to the consensus estimate of 11.530. The company issued revenue guidance of $9.7 billion-$9.8 billion, compared to the consensus revenue estimate of $9.6 billion. Concentrix also updated its Q3 2025 guidance to 2.800-2.910 EPS.

Concentrix Price Performance

NASDAQ CNXC traded up $0.96 during trading on Thursday, hitting $55.13. 1,563,656 shares of the company's stock were exchanged, compared to its average volume of 731,902. The company has a market cap of $3.52 billion, a PE ratio of 13.82, a P/E/G ratio of 0.70 and a beta of 0.56. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 1.22. Concentrix has a fifty-two week low of $36.28 and a fifty-two week high of $77.00. The stock's 50 day moving average price is $53.62 and its two-hundred day moving average price is $49.36.

Concentrix (NASDAQ:CNXC - Get Free Report) last released its quarterly earnings data on Thursday, June 26th. The company reported $2.30 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.76 by ($0.46). Concentrix had a return on equity of 16.73% and a net margin of 2.81%. Research analysts expect that Concentrix will post 10.11 EPS for the current year.

Analysts Set New Price Targets

CNXC has been the topic of a number of research reports. Wall Street Zen lowered Concentrix from a "buy" rating to a "hold" rating in a research report on Saturday, June 21st. Robert W. Baird lifted their price target on Concentrix from $62.00 to $72.00 and gave the company an "outperform" rating in a research note on Thursday. Barrington Research reaffirmed an "outperform" rating and issued a $54.00 price objective on shares of Concentrix in a research note on Tuesday. Finally, Bank of America raised their price objective on shares of Concentrix from $59.00 to $65.00 and gave the company a "neutral" rating in a report on Monday, June 9th. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Concentrix has a consensus rating of "Moderate Buy" and a consensus price target of $67.75.

Insider Activity

In other news, EVP Cormac J. Twomey sold 500 shares of the business's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $55.31, for a total value of $27,655.00. Following the transaction, the executive vice president now directly owns 39,130 shares of the company's stock, valued at $2,164,280.30. The trade was a 1.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Christopher A. Caldwell bought 1,000 shares of the business's stock in a transaction that occurred on Monday, April 21st. The shares were acquired at an average price of $46.00 per share, for a total transaction of $46,000.00. Following the transaction, the chief executive officer now owns 303,362 shares in the company, valued at $13,954,652. This represents a 0.33% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 30,944 shares of company stock valued at $1,510,158. Company insiders own 3.20% of the company's stock.

Institutional Investors Weigh In On Concentrix

A number of hedge funds have recently added to or reduced their stakes in CNXC. Geneos Wealth Management Inc. grew its position in shares of Concentrix by 532.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 620 shares of the company's stock worth $34,000 after buying an additional 522 shares during the period. Focus Partners Wealth bought a new position in Concentrix during the first quarter worth $781,000. Royal Bank of Canada grew its holdings in Concentrix by 9.5% in the first quarter. Royal Bank of Canada now owns 47,501 shares of the company's stock worth $2,643,000 after purchasing an additional 4,133 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Concentrix by 17.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 146,515 shares of the company's stock valued at $8,152,000 after purchasing an additional 21,746 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Concentrix by 75.1% in the first quarter. Goldman Sachs Group Inc. now owns 423,287 shares of the company's stock valued at $23,552,000 after purchasing an additional 181,546 shares in the last quarter. 90.34% of the stock is currently owned by institutional investors.

Concentrix Company Profile

Concentrix Corporation engages in the provision of technology-infused customer experience (CX) solutions worldwide. The company provides CX process optimization, technology innovation, front- and back-office automation, analytics, and business transformation services, across various channels of communication, such as voice, chat, email, social media, asynchronous messaging, and custom applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.